Search research articles
Contact Us
Filters
Showing results (261-270 of 289) with videos related to
Page
of 29
Sort By:
Neurology
|
October 17, 2020
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
Federica Trucco, Deborah Ridout, Mariacristina Scoto, et al.
Neurology
|
October 19, 2012
Prospective cohort study of spinal muscular atrophy types 2 and 3
Petra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Neuromuscular Disorders : NMD
|
September 19, 2024
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module
Giorgia Coratti, Matthew Civitello, Annemarie Rohwer, et al.
Brain : a Journal of Neurology
|
June 7, 2023
Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants
Christopher J Record, Mariola Skorupinska, Matilde Laura, et al.
JAMA Network Open
|
January 25, 2022
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
Jean K Mah, Paula R Clemens, Michela Guglieri, et al.
Annals of Neurology
|
May 14, 2020
GGPS1 Mutations Cause Muscular Dystrophy/Hearing Loss/Ovarian Insufficiency Syndrome
A Reghan Foley, Yaqun Zou, James E Dunford, et al.
Journal of Clinical Medicine
|
March 11, 2023
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
Georgia Stimpson, Danielle Ramsey, Amy Wolfe, et al.
European Journal of Neurology
|
June 27, 2025
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen
Giorgia Coratti, Francesca Bovis, Marika Pane, et al.
Neurology
|
August 28, 2019
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
Eric P Hoffman, Benjamin D Schwartz, Laurel J Mengle-Gaw, et al.
Journal of Neuromuscular Diseases
|
March 1, 2024
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3
Amy Wolfe, Georgia Stimpson, Danielle Ramsey, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 289) with videos related to
Sort By:
Page
of 29
Neurology
|
October 17, 2020
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
Federica Trucco, Deborah Ridout, Mariacristina Scoto, et al.
Neurology
|
October 19, 2012
Prospective cohort study of spinal muscular atrophy types 2 and 3
Petra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Neuromuscular Disorders : NMD
|
September 19, 2024
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module
Giorgia Coratti, Matthew Civitello, Annemarie Rohwer, et al.
Brain : a Journal of Neurology
|
June 7, 2023
Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants
Christopher J Record, Mariola Skorupinska, Matilde Laura, et al.
JAMA Network Open
|
January 25, 2022
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
Jean K Mah, Paula R Clemens, Michela Guglieri, et al.
Annals of Neurology
|
May 14, 2020
GGPS1 Mutations Cause Muscular Dystrophy/Hearing Loss/Ovarian Insufficiency Syndrome
A Reghan Foley, Yaqun Zou, James E Dunford, et al.
Journal of Clinical Medicine
|
March 11, 2023
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
Georgia Stimpson, Danielle Ramsey, Amy Wolfe, et al.
European Journal of Neurology
|
June 27, 2025
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen
Giorgia Coratti, Francesca Bovis, Marika Pane, et al.
Neurology
|
August 28, 2019
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
Eric P Hoffman, Benjamin D Schwartz, Laurel J Mengle-Gaw, et al.
Journal of Neuromuscular Diseases
|
March 1, 2024
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3
Amy Wolfe, Georgia Stimpson, Danielle Ramsey, et al.
Page
of 29